2017 ACVIM Forum Research Abstract Program

In this randomized, double-blind, crossover study, five skeletally mature cats were determined to be healthy based on physical examination and diagnostics including CBC, serum chemistry profile, urinalysis, and coagulation times. The cats participated in three treatment phases in which they were randomly assigned to receive either: trade name clopidogrel 18.75 mg PO SID for 7 days, generic clopidogrel 18.75 mg PO SID for 7 days, or a placebo (cellulose) PO SID for 7 days. On day 0, prior to starting the treatment, baseline platelet aggregation was assessed on a multiplate platelet aggregometer. Briefly, blood was collected into a lithium heparin tube, and platelets were activated for the assay using ADP. Platelet aggregation was repeated on day 8 to determine the percentage of platelet inhibition achieved. Information regarding potential adverse effects were recorded daily for each cat during each phase. A minimum four-week washout period occurred between each phase.